In the past 2021, Morimatsu has successfully delivered modular factories for COVID-19 vaccines developed via mRNA and adenovirus technology. At the beginning of the new year, we have passed the FAT of the bioreactor system for the recombinant protein enabling COVID-19 vaccines which then are ready for shipment. This landmark in the development of COVID-19 vaccines has once again manifested its capability to provide core equipment and integrated engineering solutions for different development technology of COVID-19 vaccines.
The construction project of a vaccine industrial park undertaken by Morimatsu is expected to produce 200 million doses annually after completion, which will greatly alleviate the current shortage of vaccines at home and abroad. Meanwhile, the industrial park will also become a high-end biological vaccine manufacturing base and international R&D innovation center of critical and extensive influence. The construction is of great significance.
The project includes numbers of 200L and 1000L bioreactors, culture medium preparation, downstream purification, CIP workstations, clean utilities and other upstream and downstream systems. The service concerned covers integrated engineering solutions including engineering design, project management, modular construction, on-site installation and commissioning.
The first batch of bioreactors to be delivered is the upmost core equipment in the whole project. Leveraging its years of technical accumulation and experience in project delivery, Morimatsu has established a complete mechanism that involves experimental testing, process scale-up design, automatic control design, manufacturing and quality control of high-quality bioreactors, and localized bioreactors, the core equipment for biopharmaceutical production, in China. Moreover, it has also kept breast with the world in advanced technologies regarding biological reactions such as gas supply, stirring, temperature control, exhaust gas, sampling, harvesting and software control.
Among the increasing projects in recent year, in addition to the large-scale bioreactor system delivered to the United States, Morimatsu is undertaking one of the largest bioreactor projects which is about to be completed and ready for shipment towards Europe. What’s more, it has also provided large-scale bioreactors for clients’ production facilities in China, thus realizing the simultaneous supply of such equipment to these three regions.
The efficient and reliable delivery has once again proved Morimatsu's outstanding professionalism and coordination, and has also laid a solid foundation for further favorable cooperation with clients. Based on its in-depth understanding of vaccine production technologies and advanced design concepts, Morimatsu continues to help customers realize rapid industrialization of vaccines, and does its best to contribute to the health of people in China and the world.
About Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd.
Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd (Stock Code: 2155.HK) is a wholly-owned subsidiary of Morimatsu International Holdings Company Limited. Morimatsu, founded in Japan and taken root in China, has developed into a multi-national company that embraces globalization, masters core technology, and gains rich experience from project implementation in diverse fields including core equipment, process systems, and engineering solutions. The company has built advanced manufacturing base in China, established affiliates in Sweden, the United States, India, and Italy, built an efficient professional globalization team, and delivered a variety of products and services to more than 40 countries and regions.
Forward-Looking Statements
The information in this press release may include some forward-looking statements. Such statements are essentially susceptible to considerable risks and uncertainties. The use of “predicted”, “believed”, “forecast”, “planned” and/or other similar words/phrases in all statements related to our company is to indicate that the statements are forward-looking ones. Our company undertakes no obligation to constantly revise such predicted statements.
Forward-looking statements are based on our company management’s current perspectives, assumptions, expectations, estimations, predictions and understanding of future affairs at the time of the making of such statements. Such statements are not guaranties of future development and are susceptible to the impact of risks, uncertainties and other factors; some are beyond the control of our company and unpredictable. Subject to the influence of future changes and development in our business, competition environment, political, economic, legal and social conditions, the actual outcomes may differ significantly from the information contained in the forward-looking statements.
